According to the press release Dimon “will be able to continue to be actively involved in [JPM’s] business and we will continue to run the company as normal.” We might point out that being able to be involved is not the same thing as being involved.
It is natural that the bank wants to minimize the impact of Dimon’s treatments on the bank’s operation, but someone whose name is not Jamie Dimon will be running the bank’s daily operations, and the bank needs to make clear who that is. The bank has no official succession plan, and at the very least Dimon’s illness should prod J.P. Morgan into action on that front.
The emphasis that Dimon and, apparently J.P. Morgan’s board, put on the curable nature of Dimon’s cancer and the relatively short treatment period could give one pause about the board’s willingness to work through a succession plan. While this may strike some as inappropriate and even macabre, the fact that J.P. Morgan has no such plan is the issue. Dimon’s health just draws a line under the board’s dilatoriness.
The bank’s stock was down about 0.5% in premarket trading Wednesday, at $57.31 in a 52-week range of $50.06 to $61.48.
ALSO READ: Weak Trading and Lower Investment Banking Revenues May Hurt These Banks
Top Gaining Stocks
Top Losing Stocks